Suzan S Ibrahim1,2, Nivine I Ragy3, Noha A Nagy3*, Hala El-kammar4, Asmaa M Elbakry5,6 and Ola M Ezzatt1³

¹Department of Oral Medicine, Periodontology and Oral Diagnosis, Faculty of Dentistry, Ain Shams University, Cairo, Egypt
²Department of Oral Medicine, Periodontology Oral Diagnosis and Radiology, Faculty of Dental Medicine, Nahda University, Beni Suef, Egypt
³Department of Oral Medicine, Periodontology and Oral Diagnosis, Faculty of Oral and Dental Medicine, Future University in Egypt, Cairo, Egypt
⁴Department of Oral Pathology, Faculty of Oral and Dental Medicine, Future University in Egypt, Cairo, Egypt
⁵Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
⁶Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt

*Corresponding Author: Noha A Nagy, Department of Oral Medicine, Periodontology and Oral Diagnosis, Faculty of Oral and Dental Medicine, Future University in Egypt, Cairo, Egypt.

Received: November 06, 2023; Published: November 28, 2023

Abstract

Background and Aim: Tacrolimus (TAC) is an immunomodulator drug. This study aimed to evaluate the clinical effectiveness of topical TAC patches for symptomatic treatment of erosive/atrophic oral lichen planus (OLP).

Materials and Methods: Twenty patients complaining of symptomatic erosive/atrophic OLP were treated by applying topical TAC 0.1% patch twice daily for 8 weeks. Each patient was assessed for painful symptoms using visual analog scale (VAS) at baseline, 2, 4, and 8 weeks of treatment, and were followed for 4 weeks of treatment free period. The clinical improvement grading (CIG) was also calculated for the study intervals.

Results: TAC patch resulted in significant reduction in VAS [-70.21% (15.82)] within the first two weeks, and this was observed throughout the treatment period, all patients were symptoms free and showed dramatic clinical improvement with most of the lesions disappeared by the end of the study.

Conclusion: Tacrolimus 0.1% patch was well tolerated and significantly reduced painful symptoms and induced rapid and sustained clinical improvement in management of symptomatic OLP with minimal and transient side effects.

Keywords:Oral Lichen Planus; Tacrolimus; Patch; Visual Analog Scale; Clinical Improvement Grading

References

1. Li Changchang., et al. “Global Prevalence and Incidence Estimates of Oral Lichen Planus: A Systematic Review and Meta-analysis”. JAMA Dermatology2 (2020): 172-181.
2. Gorouhi Farzam., et al. “Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis”. The Scientific World Journal (2014): 742826.
3. Lodi Giovanni., et al. “Interventions for treating oral lichen planus: corticosteroid therapies”. The Cochrane Database of Systematic Reviews2 (2020): CD001168.
4. Kapturczak MH., et al. “Pharmacology of calcineurin antagonists”. Transplantation Proceedings2 (2004): 25S-32S.
5. Shilpa PS., et al. “Topical tacrolimus in the management of oral lichen planus: literature review”. Journal of the California Dental Association3 (2014): 165-170.
6. Ibrahim Suzan S and Hala H Hazzaa. “Topical pimecrolimus effect on Fas inducing apoptosis in oral lichen planus: a clinical immunohistochemical study”. Journal of Oral Pathology and Medicine 41,4 (2012): 315-21.
7. Ezzatt Ola M and Iman M Helmy. “Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial”. Clinical Oral Investigations2 (2019): 947-956. 
8. Sun S-L., et al. “Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis”. The British Journal of Dermatology6 (2019): 1166-1176.
9. da Silva., et al. “Efficacy of topical non-steroidal immunomodulators in the treatment of oral lichen planus: a systematic review and meta-analysis”. Clinical Oral Investigations25,9 (2021): 5149-5169.
10. Alves Thais FR., et al. “Bilayer Mucoadhesive Buccal Film for Mucosal Ulcers Treatment: Development, Characterization, and Single Study Case”. Pharmaceutics7 (2020): 1-24.
11. Ashwathy P., et al. “Development and Characterization of Buccal Film: Tacrolimus as A Model Drug”. Journal of Medical Biomedical and Applied Sciences 7 (2019): 207-211.
12. , et al. “Promote Recurrent Aphthous Ulcer Healing with Low Dose Prednisolone Bilayer Mucoadhesive Buccal Film”. Current Drug Delivery 14.1 (2017): 123-135.
13. Rad Maryam., et al. “Correlation between clinical and histopathologic diagnoses of oral lichen planus based on modified WHO diagnostic criteria”. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics6 (2009): 796-800.
14. Hettiarachchi Pilana., et al. “Comparison of topical tacrolimus and clobetasol in the management of symptomatic oral lichen planus: A double-blinded, randomized clinical trial in Sri Lanka”. Journal of Investigative and Clinical Dentistry4 (2017): 12237.
15. Colley HE., et al. “Pre-clinical evaluation of novel mucoadhesive bilayer patches for local delivery of clobetasol-17-propionate to the oral mucosa”. Biomaterials 178 (2018): 134-146.
16. Scott J and EC Huskisson. “Graphic representation of pain”. Pain2 (1976): 175-184.
17. Gorouhi Farzam., et al. “Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus”. Journal of the American Academy of Dermatology5 (2007): 806-813.
18. Pereira U., et al. “Mechanisms of the sensory effects of tacrolimus on the skin”. The British Journal of Dermatology1 (2010): 70-77.
19. Ahmed S., et al. “Comparison Between Uses of Topical Tacrolimus and Triamcinolone Ointment for the Treatment of Oral Lichen Planus”. Update Dental College Journal1 (2018): 17-21.

Citation

Citation: Noha A Nagy., et al. “Evaluation of Muco-adhesive Tacrolimus Patch in Oral Lichen Planus".Acta Scientific Dental Sciences 7.12 (2023): 51-55.

Copyright

Copyright: © 2023 Noha A Nagy., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.